Last reviewed · How we verify
GSK investigational vaccine GSK2340269A — Competitive Intelligence Brief
phase 3
Vaccine
Immunology/Oncology
Biologic
Live · refreshed every 30 min
Target snapshot
GSK investigational vaccine GSK2340269A (GSK investigational vaccine GSK2340269A) — GlaxoSmithKline. GSK2340269A is an investigational vaccine designed to stimulate immune responses against specific tumor-associated antigens or infectious disease targets.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK investigational vaccine GSK2340269A TARGET | GSK investigational vaccine GSK2340269A | GlaxoSmithKline | phase 3 | Vaccine | ||
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| Attenuated Hepatitis A Vaccine, H2 Strain | Attenuated Hepatitis A Vaccine, H2 Strain | Jiangsu Province Centers for Disease Control and Prevention | marketed | Live attenuated vaccine | Hepatitis A virus | |
| Bivalent OPV 2 week interval | Bivalent OPV 2 week interval | International Centre for Diarrhoeal Disease Research, Bangladesh | marketed | vaccine | ||
| Shingrix | shingrix | GSK | marketed | Vaccine | Varicella zoster virus | |
| Twinrix for ATN 025 | Twinrix for ATN 025 | University of North Carolina, Chapel Hill | marketed | Vaccine | Hepatitis A virus and Hepatitis B virus |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (Vaccine class)
- GlaxoSmithKline · 16 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
- Pfizer · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
- Henogen · 3 drugs in this class
- Pfizer Inc. · 2 drugs in this class
- Sanofi · 2 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
- BioNTech · 2 drugs in this class
- Merck Sharp & Dohme LLC · 2 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK investigational vaccine GSK2340269A CI watch — RSS
- GSK investigational vaccine GSK2340269A CI watch — Atom
- GSK investigational vaccine GSK2340269A CI watch — JSON
- GSK investigational vaccine GSK2340269A alone — RSS
- Whole Vaccine class — RSS
Cite this brief
Drug Landscape (2026). GSK investigational vaccine GSK2340269A — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk-investigational-vaccine-gsk2340269a. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab